Clinical Trial Update: A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing a once-weekly combination therapy IcoSema (insulin icodec + semaglutide) to daily insulin glargine with insulin aspart in people with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IcoSema (insulin icodec and semaglutide)
• Insulin Glargine (insulin glargine)
• Insulin aspart (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED